Scinai Immunotherapeutics is a NASDAQ-listed biopharmaceutical company that provides boutique biologics CDMO services through its Scinai Bioservices business unit, alongside its own I&I therapeutics pipeline. The CDMO offers end-to-end drug development and manufacturing from molecule selection through Phase 3 manufacturing, with over 20 years of experience in recombinant protein development. Scinai acquired a manufacturing site in Yavne, Israel from Recipharm and established a US subsidiary (Scinai Bioservices Inc.).
boutique biologics CDMO, recombinant protein manufacturing, nanobody (VHH/nanoAb) development, upstream fermentation, downstream purification, cGMP manufacturing
1 site worldwide
No reviews available yet.
No documents available.